


TCG Lifesciences to offer CDMO services in US via subsidiary GreenChem Inc

04 February 2021 | News

It aims at utilising its deep expertise in areas of automated catalysis/reaction screening, reaction optimisation, and continuous chemistry to support the needs of the big pharma and biotech industry



Kolkata based TCG Lifesciences Pvt Ltd, a company controlled by New York-based The Chatterjee Group (TCG), has announced the expansion of its operations in the US with the establishment of TCG GreenChem Inc, a subsidiary of TCG Lifesciences Pvt Ltd, to provide contract development and manufacturing company (CDMO) services to global clients.

TCG GreenChem, Inc, offers seamless CMC development services including process research & development and delivery of cGMP APIs. It aims at utilising its deep expertise in areas of automated catalysis/reaction screening, reaction optimisation, and continuous chemistry to support the needs of the big pharma and biotech industry.

TCG GreenChem, Inc is developing novel, efficient and low-cost processes for selected COVID-19 virus-related medicines and other antiviral drugs using new technologies and process schemes under contract with research foundations/hospitals, US Government, and selected biotech companies. It is also engaged with developing several selected drugs with backward integration all the way to the starting materials within US shores.

Swapan Bhattacharya, Managing Director, TCG Lifesciences Pvt Ltd commented, "TCG GreenChem has an exceptional management team, technological expertise and know-how, which is critical for the development of architecturally complex intermediates and APIs by utilising state-of-the-art synthetic organic chemistry."

Dr Chris H Senanayake, CEO and CSO, TCG GreenChem, Inc added, "Our mission is to create a 'technology innovator' CDMO, to partner with the pharmaceutical, biotechnology, and generic industries in delivering integrated, accelerated, and economical services utilising green sustainable technologies with a global footprint. Leveraging our knowledge of drug development and commercialisation, we want to be the drug development engine 'accelerating molecules to medicines' by advancing preclinical candidates into phase I and beyond, for our clients and partners."